Navigation Links
Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease
Date:10/27/2008

Oral 5-Aminosalicylates Will Continue to be Used in Early Lines of Therapy, According to a New Report from Decision Resources

WALTHAM, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade is currently the leading biologic for Crohn's disease, but Abbott/Eisai's Humira will soon become the first-choice among biologics.

Patient-level claims data indicate that Remicade currently captures a larger share of Crohn's disease patients on every line of therapy than Humira. However, 56 and 65 percent of surveyed gastroenterologists and primary care physicians say that, over the next two years, they will increase their use of Humira on the first and second lines of therapy, respectively. This shift will occur because Humira is easier to use--it can be self injected in the privacy of one's home versus having to go to the physician's office as is the case with Remicade which is administered intravenously. In addition, both gastroenterologists and primary care physicians say they will increase their use of Humira as a maintenance therapy.

According to interviewed experts, physicians are increasingly moving patients to biologics early in treatment.

"Moving up in lines of therapy means an expanded potential patient population for these agents," stated Michael Malecki, Ph.D., analyst at Decision Resources. "Because biologics are much more expensive than conventional agents, the trend of using them earlier in therapy will result in a net market expansion in terms of dollars."

The new report entitled Treatment Algorithms in Crohn's Disease also finds that oral 5-aminosalicylates will continue to be used in early lines of therapy for patients with mild disease. Among oral 5-aminosalicylates, Shire's Lialda has more convenient dosing. Because of this clinical advantage, surveyed physicians indicated that they intend to move patients to Lialda from both Procter & Gamble/Giuliani's Asacol and Shire/Ferring/Nisshin/Kyorin Seiyaku's Pentasa over the next two years.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

The reports can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst and are welcome to attend our upcoming webinar entitled Biologics Penetration of Early Lines of Therapy in Psoriasis, Crohn's and Rheumatoid Arthritis: Implications for Existing and Emerging Brands. The webinar will be held on Wednesday, November 19, 2008 at 10 a.m. EST. For more information, please contact Natalia Morales at 781.296.2691 or e-mail at nmorales@dresources.com.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Natalia Morales Elizabeth Marshall

Decision Resources Decision Resources, Inc.

781-296-2691 781-296-2563

nmorales@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
2. Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
3. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
4. Although Remicade and Humira Are Being Increasingly Prescribed for Crohns Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
5. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
6. Data Show that Abbotts HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
7. HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
8. New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
9. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
10. Pill Equals Injection in Preventing Clots After Hip Replacement
11. Its Probably Time to Replace Your Vehicles Cabin Air Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 31, 2016 , ... Spartan Bioscience today introduced the Spartan ... convenience. , The Cube is exceptionally small—it takes up the space of a ... into any space, whether in a hospital, doctor’s office, or pharmacy. , The ...
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, ... know – London is home to Ontario’s leading day spa and one of Canada’s ... Tamba began with a unique concept to combine spa services with hair and ...
(Date:5/31/2016)... ... ... In his latest video, renowned AstroNumerologist Jesse Kalsi reveals ... candidate Donald Trump as an example, Kalsi describes the way AstroNumerology conveys the ... numbers up,” says Kalsi. “It is about looking at each individual number, since ...
(Date:5/31/2016)... ... 31, 2016 , ... Interest is on the rise for using the CRISPR-Cas9 ... tool for RNAi hit validation. A key reason may be that high-throughput synthesis—combined with ... CRISPR RNA (crRNA) collections in arrayed formats. , Arrayed crRNA screens ...
(Date:5/31/2016)... ... , ... In a recent interview on The Greenburgh Report radio show hosted ... WVOX (1460 AM), leading medical insurance advocate Adria Goldman Gross discussed several eye-opening ... maelstrom.” , During the interview with Mr. Feiner that aired on May 7, ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 2016 194 Mitgliedsstaaten ... Eliminierung von viraler Hepatitis    Am ... eingegangen, virale Hepatitis bis 2030 zu eliminieren. ... Assembly haben sich die Staaten einstimmig dafür entschieden, ... Viral Hepatitis Strategy) zu verabschieden, was das bisher ...
(Date:5/30/2016)... , May 30, 2016 ... "Healthcare Analytical Testing Services Market by Type (Stability, ... Services), by End User (Pharmaceutical Companies, Medical Device ... MarketsandMarkets, The market witnessed healthy growth during the ... a CAGR of 11.3% between 2016 and 2021 ...
(Date:5/30/2016)... , May 30, 2016 ... 2016" market research report with comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
Breaking Medicine Technology: